Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors DOI Creative Commons
Antongiulio Faggiano, Flaminia Russo, Virginia Zamponi

et al.

Journal of Neuroendocrinology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 26, 2024

Abstract Dyslipidemia is a potential unfavorable prognostic factor in neuroendocrine tumors (NETs); conversely, statins proved to have antiproliferative effects NET cell lines and could be helpful therapeutic strategy for these patients. The main objective of this observational cohort retrospective study explore the associations between dyslipidemia progression evaluate influence context. 393 patients with histologically confirmed gastroenteropancreatic or bronchopulmonary NETs from six Italian centres didicated diagnosis therapy were included. included 123 dyslipidemia, 81 which taking statins. Clinicopathological data, including patient demographics, tumor characteristics, treatment details as well prevalence, timing hypolipemic collected. outcome measure used progression‐free survival (PFS). Among patients, (31.3%) had dyslipidemia. Statins by (65.8%) dyslipidemic mostly atorvastatin. Median PFS was 87 months overall, 124 non‐dyslipidemic 72 ( p = .268). Dyslipidemic on significantly better median (108 months) than those not (26 months; .024). Recurrence‐free (RFS) also evaluated, but no significant differences found. In conclusion, while lower compared difference statistically significant. Statin associated improved among suggesting effect NETs. These findings warrant further investigation substantiate role management

Language: Английский

Impact of poorly controlled type II diabetes mellitus on chemoresistance in colorectal cancer DOI
Aditya H. Gaur, Rick Maity, Arkadeep Dhali

et al.

World Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: 31(11)

Published: March 12, 2025

Type 2 diabetes mellitus (T2DM) significantly elevates the risk of colorectal cancer (CRC) and complicates its treatment by promoting chemoresistance. Poor glycemic control has been linked to exacerbated CRC progression diminished chemotherapy efficacy, impacting patient outcomes through various mechanisms such as oxidative stress, activation metabolic pathways, altered protein modifications that hinder apoptosis enhance tumor survival. Clinical evidence shows T2DM patients experience higher rates chemoresistance reduced disease-free survival overall compared non-diabetic patients. Specifically, those with poor exhibit increased poorer metrics. Antidiabetic treatments, including metformin, acarbose, gliclazide, show promise in improving response management, potentially enhancing outcomes. Addressing this challenge requires a comprehensive, multidisciplinary approach involving oncologists, endocrinologists, surgeons optimize care. Integrated strategies prioritize are essential for reducing T2DM.

Language: Английский

Citations

0
Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions DOI Creative Commons
Rosaria Maddalena Ruggeri, Erika Grossrubatscher,

Eleonora Ciocca

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

Neuroendocrine tumors (NET) are frequently associated with glycemic disorders, such as prediabetes or diabetes, which may result from either surgical medical treatments hormonal hypersecretion by the tumor itself. Moreover, pre-existing diabetes is a known risk factor for NET development, metabolic control and antidiabetic therapies potentially influencing progression. The complex interplay between NET, share several molecular pathways, has spurred interest in anti-cancer effects of medications. This particularly relevant new drugs continue to emerge, including sodium-glucose cotransporter-2 (SGLT2) inhibitors incretin-based therapies, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists dual GIP/GLP- 1 R agonists. review explores impact these novel pharmacological options on development progression through comprehensive analysis pre-clinical clinical studies, purpose evaluate safety feasibility introducing treatment NETs patients. We conducted search online databases, PubMed, ISI Web Science, Scopus, studies assessing therapeutic potential mechanisms action incretins SGLT2 patients NET. These exhibit promising anticancer properties, inhibiting cell proliferation inducing apoptosis, though concerns about certain cancer risks remain. Based current evidence, benefits outweigh any risks, leading proposal tailored management algorithms patients, factoring aetiology, comorbidities, life expectancy.

Language: Английский

Citations

0
Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies DOI Creative Commons
Marco Gallo, Angioletta Lasagna,

Valerio Renzelli

et al.

Journal of Endocrinological Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Language: Английский

Citations

0
Preliminary guidelines for the detection and management of drug-related problems in cancer patients with type 2 diabetes mellitus: a practical resource for oncology pharmacists DOI

Chloé Gossery,

Justine Clarenne, Sara Barraud

et al.

Supportive Care in Cancer, Journal Year: 2024, Volume and Issue: 32(12)

Published: Nov. 14, 2024

Language: Английский

Citations

0
Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors DOI Creative Commons
Antongiulio Faggiano, Flaminia Russo, Virginia Zamponi

et al.

Journal of Neuroendocrinology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 26, 2024

Abstract Dyslipidemia is a potential unfavorable prognostic factor in neuroendocrine tumors (NETs); conversely, statins proved to have antiproliferative effects NET cell lines and could be helpful therapeutic strategy for these patients. The main objective of this observational cohort retrospective study explore the associations between dyslipidemia progression evaluate influence context. 393 patients with histologically confirmed gastroenteropancreatic or bronchopulmonary NETs from six Italian centres didicated diagnosis therapy were included. included 123 dyslipidemia, 81 which taking statins. Clinicopathological data, including patient demographics, tumor characteristics, treatment details as well prevalence, timing hypolipemic collected. outcome measure used progression‐free survival (PFS). Among patients, (31.3%) had dyslipidemia. Statins by (65.8%) dyslipidemic mostly atorvastatin. Median PFS was 87 months overall, 124 non‐dyslipidemic 72 ( p = .268). Dyslipidemic on significantly better median (108 months) than those not (26 months; .024). Recurrence‐free (RFS) also evaluated, but no significant differences found. In conclusion, while lower compared difference statistically significant. Statin associated improved among suggesting effect NETs. These findings warrant further investigation substantiate role management

Language: Английский

Citations

0